1 most recent filing and news item mentioning BLLN. Updated every 60 seconds.
EarningsAug 5, 2026Positive
The company reported a 64% increase in Q2 revenue, driven by growth in both prenatal and oncology testing. Management reiterated full-year guidance for $450M to $465M in revenue.
View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.